Biomarkers in Heart Failure.
作者信息
Spineti Pedro Pimenta de Mello
机构信息
Hospital Universitário Pedro Ernesto, Rio de Janeiro, RJ - Brazil.
Hospital Unimed-Rio, Rio de Janeiro, RJ - Brazil.
出版信息
Arq Bras Cardiol. 2019 Sep 2;113(2):205-206. doi: 10.5935/abc.20190167.
Abstract
摘要
相似文献
1
Biomarkers in Heart Failure.心力衰竭中的生物标志物
Arq Bras Cardiol. 2019 Sep 2;113(2):205-206. doi: 10.5935/abc.20190167.
2
Lipoprotein(a) and Heart Failure: Another Reason to Study Interventions in Patients With Very High Levels of Lipoprotein(a)?脂蛋白(a)与心力衰竭：这是研究对脂蛋白(a)水平极高的患者进行干预的另一个理由吗？
JACC Heart Fail. 2016 Jan;4(1):88-9. doi: 10.1016/j.jchf.2015.11.001.
3
[Biomarkers in cardiology--state of the art 2007].[2007年心脏病学中的生物标志物——最新进展]
Wien Med Wochenschr. 2007 Feb;157(3-4):48-56. doi: 10.1007/s10354-007-0372-3.
4
The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.脂蛋白(a)与首次心力衰竭住院的关联：社区动脉粥样硬化风险研究
Atherosclerosis. 2017 Jul;262:131-137. doi: 10.1016/j.atherosclerosis.2017.05.014. Epub 2017 May 12.
5
Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome.肾损伤分子-1 和 N-乙酰-β-D-氨基葡萄糖苷酶在慢性心力衰竭中的作用：心肾综合征的潜在生物标志物。
Eur J Heart Fail. 2011 Oct;13(10):1104-10. doi: 10.1093/eurjhf/hfr102. Epub 2011 Aug 16.
6
Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population.脂蛋白(a)水平升高、LPA 风险基因型与普通人群心力衰竭风险增加。
JACC Heart Fail. 2016 Jan;4(1):78-87. doi: 10.1016/j.jchf.2015.08.006. Epub 2015 Dec 2.
7
High-density lipoprotein cholesterol levels and risk of death in chronic heart failure patients referred for heart transplant evaluation.接受心脏移植评估的慢性心力衰竭患者的高密度脂蛋白胆固醇水平与死亡风险
J Heart Lung Transplant. 2010 Mar;29(3):386-7. doi: 10.1016/j.healun.2009.08.026. Epub 2009 Oct 28.
8
Management of chronic heart failure: biomarkers, monitors, and disease management programs.慢性心力衰竭的管理：生物标志物、监测器和疾病管理方案。
Ann Glob Health. 2014 Jan-Feb;80(1):46-54. doi: 10.1016/j.aogh.2013.12.005. Epub 2013 Dec 25.
9
Utility of temporal profiles of new cardio-renal and pulmonary candidate biomarkers in chronic heart failure.新的心肾和肺候选生物标志物时间谱在慢性心力衰竭中的应用。
Int J Cardiol. 2019 Feb 1;276:157-165. doi: 10.1016/j.ijcard.2018.08.001. Epub 2018 Aug 3.
10
Nonfasting Triglycerides, Low-Density Lipoprotein Cholesterol, and Heart Failure Risk: Two Cohort Studies of 113 554 Individuals.非空腹甘油三酯、低密度脂蛋白胆固醇与心力衰竭风险：113554 例个体的两项队列研究。
Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):464-472. doi: 10.1161/ATVBAHA.117.310269. Epub 2017 Nov 2.
本文引用的文献
1
High Level of Lipoprotein(a) as Predictor for Recurrent Heart Failure in Patients with Chronic Heart Failure: a Cohort Study.脂蛋白(a)水平高可预测慢性心力衰竭患者心力衰竭再发：一项队列研究。
Arq Bras Cardiol. 2019 Jul 18;113(2):197-204. doi: 10.5935/abc.20190120.
2
Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.心血管生物标志物可预测瑞典心力衰竭患者出院后的再住院风险和死亡率。
ESC Heart Fail. 2019 Oct;6(5):992-999. doi: 10.1002/ehf2.12486. Epub 2019 Jul 24.
3
[Not Available].[无可用内容]。
Arq Bras Cardiol. 2018 Sep;111(3):436-539. doi: 10.5935/abc.20180190.
4
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.生物标志物在心衰的预防、评估和管理中的作用：美国心脏协会的科学声明。
Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26.
5
Benchmarks for the assessment of novel cardiovascular biomarkers.新型心血管生物标志物评估的基准
Circulation. 2007 Feb 27;115(8):949-52. doi: 10.1161/CIRCULATIONAHA.106.683110.
6
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.生物标志物与替代终点：首选定义及概念框架
Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.
Zotero 插件